Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Early Stage Colon Cancer
NCT04231526Phase 2Withdrawn
- Sponsor
- University of Chicago
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in colon cancer (2 arms), sponsored by University of Chicago. Primary endpoint: Feasibility of neoadjuvant pembrolizumab at 14 months. Planned start May 2020; status: withdrawn.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04231526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231526.